Evidence map›Paper›PMID 39346995›Full record

ArticleBiomedical optics express2024

Furu Zhang, Katherine Kovalick, Achyut Raghavendra, Somayyeh Soltanian-Zadeh, Sina Farsiu, Daniel X Hammer, Zhuolin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical optics express, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Frontiers in ophthalmology · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Furu ZhangCenter for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Katherine KovalickCenter for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Achyut RaghavendraCenter for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID https://orcid.org/0000-0002-2463-4580
Somayyeh Soltanian-ZadehDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Sina FarsiuDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID https://orcid.org/0000-0003-4872-2902
Daniel X HammerCenter for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID https://orcid.org/0000-0003-0532-1914
Zhuolin LiuCenter for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.ORCID https://orcid.org/0000-0001-8019-2054

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
NEI NIH HHS P30 EY005722
6 · The paper itself

Abstract

Retinal ganglion cells play an important role in human vision, and their degeneration results in glaucoma and other neurodegenerative diseases. Imaging these cells in the living human retina can greatly improve the diagnosis and treatment of glaucoma. However, owing to their translucent soma and tight packing arrangement within the ganglion cell layer (GCL), successful imaging has only been achieved with sophisticated research-grade adaptive optics (AO) systems. For the first time we demonstrate that GCL somas can be resolved and cell morphology can be quantified using non-AO optical coherence tomography (OCT) devices with optimal parameter configuration and post-processing.

Identifiers

PMID39346995
PMCPMC11427184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.